

AGN 193109

Catalog No: tcsc0035405



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg



Specifications

CAS No:

171746-21-7

Formula:

$C_{28}H_{24}O_2$

Pathway:

Metabolic Enzyme/Protease

Target:

RAR/RXR

Purity / Grade:

>98%

Solubility:

DMSO : 2 mg/mL (5.10 mM; Need warming)

Observed Molecular Weight:

392.49


Product Description

AGN 193109 is a retinoid analog, and acts as a specific and highly effective antagonist of **retinoic acid receptors (RARs)**, with **K_d**s of 2 nM, 2 nM, and 3 nM for **RAR α** , **RAR β** , and **RAR γ** , respectively.

IC50 & Target: Kd: 2 nM (RAR α), 2 nM (RAR β), 3 nM (RAR γ)^[1]

In Vitro: AGN 193109 is a highly effective antagonist of retinoic acid receptors, with K_ds of 2 nM, 2 nM, and 3 nM for RAR α , RAR β , and RAR γ , respectively. AGN 193109 is completely RAR specific, because it does not bind to or transactivate through any of the RXRs^[1]. AGN 193109 (100 nM) inhibits the TTNPB (a retinoic acid receptor agonist)-dependent morphological change in ECE16-1 cells. AGN193109 half-reverses retinoid-dependent growth suppression at 10 nM, and completely shows this effect at 100 nM in ECE16-1 cells. AGN193109 (100 nM) also eliminates TTNPB-induced decrease in levels of K5, K6, K14, K16, and K17 and increase in levels of K7, K8, and K19^[2].

In Vivo: AGN 193109 (1.15 μ mol/kg) does not causes overt toxicity and has no effect on spleen weight on the mice, but it suppresses TTNPB-induced increase in spleen weight of the mice. AGN 193109 also significantly reduces the cutaneous toxicity induced by ATRA. AGN 193109 (0.30 or 1.20 μ mol/kg) by topical treatment significantly reduces both weight loss and cutaneous toxicity caused by oral TTNPB cotreatment^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!